Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucinous Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MUC5AC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MUC5AC Recombinant Protein (HEK293 Expressed, Native Glycosylation) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View MUC5AC Products |
| Gene Delivery | MUC5AC Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View MUC5AC Products |
| Benchmark Ab | Anti-MUC5AC Recombinant Antibody (Sequence of NPC-1C / NEO-102) Recombinant positive control for binding assays. |
View MUC5AC Products |
| Validator | MUC5AC siRNA Set For target knockdown verification. |
View MUC5AC Products |
| Related Target A | MUC5B Critical homolog for off-target counter-screening to avoid pulmonary toxicity. |
View MUC5B Products |
| Related Target B | MUC1 Synergistic mucin target co-expressed in epithelial malignancies. |
View MUC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with normal airway mucins (MUC5B) | Human MUC5AC and MUC5B ortholog proteins strictly verified by Mass Spectrometry for structural identity. |
| Glycan-dependent epitope presentation | HEK293 host expression ensures native human glycosylation (crucial for tumor-associated glyco-epitope binding). |
| Lack of positive control references | Clinical Benchmark Antibodies (NPC-1C sequence biosimilar) included for assay calibration. |
| Assay noise from non-specific binding | High Purity (>95%) and Endotoxin Controlled (<1 EU/ug) specifications limit background interference. |
Live MUC5AC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC5AC therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and CAR-T cell therapies. MUC5AC is a large, heavily glycosylated gel-forming mucin aberrantly overexpressed in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), gastric cancer, and non-small cell lung cancer (NSCLC). As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glyco-epitopes of MUC5AC to minimize on-target, off-tumor toxicities in healthy mucosal tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Precision Biologics, Academic Institutions | Pancreatic Cancer, Colorectal Cancer | Internalization Assay (Requires high-purity, natively glycosylated MUC5AC ECD-Fc) |
| CAR-T / Cell Therapy | Biotech Startups, Clinical Centers | Solid Tumors (MUC5AC positive) | Specificity Validation (Requires MUC5AC vs MUC5B cross-reactivity panel) |
| Monoclonal Antibodies (mAb) | Precision Biologics (NPC-1C) | Pancreatic and Colorectal Malignancies | Epitope Mapping (Requires sequence-verified mutant recombinant proteins) |